101 related articles for article (PubMed ID: 26421296)
1. Initial Experience of Sorafenib Neoadjuvant Therapy Combined with Retroperitoneoscopy in Treating T2 Large Renal Carcinoma.
Lin CH; Yuan HJ; Wang K; Wu JT; Liu QZ; Yu SQ; Men CP; Gao ZL; Wang J
Biomed Res Int; 2015; 2015():609549. PubMed ID: 26421296
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib neoadjuvant therapy in the treatment of high risk renal cell carcinoma.
Zhang Y; Li Y; Deng J; Ji Z; Yu H; Li H
PLoS One; 2015; 10(2):e0115896. PubMed ID: 25647522
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma.
Muselaers CH; Stillebroer AB; Desar IM; Boers-Sonderen MJ; van Herpen CM; de Weijert MC; Langenhuijsen JF; Oosterwijk E; Leenders WP; Boerman OC; Mulders PF; Oyen WJ
J Nucl Med; 2014 Feb; 55(2):242-7. PubMed ID: 24396030
[TBL] [Abstract][Full Text] [Related]
5. Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma.
Hatiboglu G; Hohenfellner M; Arslan A; Hadaschik B; Teber D; Radtke JP; Hallscheidt P; Tolstov Y; Roth W; Grüllich C; Huesing J; Duensing S; Pahernik S
Langenbecks Arch Surg; 2017 Jun; 402(4):637-644. PubMed ID: 28012035
[TBL] [Abstract][Full Text] [Related]
6. Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC).
Harshman LC; Yu RJ; Allen GI; Srinivas S; Gill HS; Chung BI
Urol Oncol; 2013 Apr; 31(3):379-85. PubMed ID: 21353796
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study.
Jäger D; Ma JH; Mardiak J; Ye DW; Korbenfeld E; Zemanova M; Ahn H; Guo J; Leonhartsberger N; Stauch K; Böckenhoff A; Yu J; Escudier B
Clin Genitourin Cancer; 2015 Apr; 13(2):156-64.e1. PubMed ID: 25444666
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant sorafenib treatment of clear cell renal cell carcinoma and release of circulating tumor fragments.
Kats-Ugurlu G; Oosterwijk E; Muselaers S; Oosterwijk-Wakka J; Hulsbergen-van de Kaa C; de Weijert M; van Krieken H; Desar I; van Herpen C; Maass C; de Waal R; Mulders P; Leenders W
Neoplasia; 2014 Mar; 16(3):221-8. PubMed ID: 24726142
[TBL] [Abstract][Full Text] [Related]
9. Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib.
Khandani AH; Cowey CL; Moore DT; Gohil H; Rathmell WK
Nucl Med Commun; 2012 Sep; 33(9):967-73. PubMed ID: 22714005
[TBL] [Abstract][Full Text] [Related]
10. Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects.
Kondo T; Hashimoto Y; Kobayashi H; Iizuka J; Nishikawa T; Nakano M; Tanabe K
Jpn J Clin Oncol; 2010 Dec; 40(12):1173-9. PubMed ID: 20696817
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study.
Kim SH; Kim S; Nam BH; Lee SE; Kim CS; Seo IY; Kim TN; Hong SH; Kwon TG; Seo SI; Joo KJ; Song K; Kwak C; Chung J
PLoS One; 2015; 10(8):e0135165. PubMed ID: 26308612
[TBL] [Abstract][Full Text] [Related]
12. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
[TBL] [Abstract][Full Text] [Related]
13. Relationship of pathologic factors to efficacy of sorafenib treatment in patients with metastatic clear cell renal cell carcinoma.
Araki H; Tsuzuki T; Kimura T; Tanaka K; Yamada S; Sassa N; Yoshino Y; Hattori R; Gotoh M
Am J Clin Pathol; 2015 Apr; 143(4):492-9. PubMed ID: 25780000
[TBL] [Abstract][Full Text] [Related]
14. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
15. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma.
Cowey CL; Amin C; Pruthi RS; Wallen EM; Nielsen ME; Grigson G; Watkins C; Nance KV; Crane J; Jalkut M; Moore DT; Kim WY; Godley PA; Whang YE; Fielding JR; Rathmell WK
J Clin Oncol; 2010 Mar; 28(9):1502-7. PubMed ID: 20159822
[TBL] [Abstract][Full Text] [Related]
17. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of First-Line Sorafenib Treatment for Metastatic Renal Cell Carcinoma in Kidney Transplant Patients: A Single-Center Experience With Four Cases.
Ishihara H; Kondo T; Tanabe K
Ther Apher Dial; 2017 Aug; 21(4):414-416. PubMed ID: 28593648
[No Abstract] [Full Text] [Related]
19. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group.
Tafreshi A; Thientosapol E; Liew MS; Guo Y; Quaggiotto M; Boyer M; Davis ID
Asia Pac J Clin Oncol; 2014 Mar; 10(1):60-5. PubMed ID: 24152417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]